Novo Holdings has agreed to acquire a 24.9 per cent of the equity in Envirotainer in partnership with the private equity firm Cinven.
The Danish life science investor says Envirotainer was an attractive investment due to its innovative product offering; consistent service delivery and global delivery capability; attractive market due to the rise in biopharma sales; and global growth opportunities with Cinven and Novo supporting development in technology.
Envirotainer chief executive officer, Michael Berg says: “We are pleased to welcome Novo Holdings as a partner alongside Cinven in Envirotainer, where we see great value from Novo Holdings healthcare expertise and pharmaceutical market knowledge to further develop the customer service offering of Envirotainer.”
Novo Holdings senior director, Samir Kamal says: “Envirotainer is a very attractive investment opportunity for Novo Holdings. The company is a leading player and is in an excellent position to further benefit from the increasingly important demand for temperature controlled biopharma logistics.
“We are excited about this investment and look forward to, together with the management team and Cinven, be part of further developing Envirotainer.”